Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel agents in the treatment of multiple myeloma: a review about the future
Leonard Naymagon, Maher Abdul‐Hay
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1143
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, et al.
Blood (2017) Vol. 130, Iss. 22, pp. 2401-2409
Open Access | Times Cited: 460
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, et al.
Blood (2017) Vol. 130, Iss. 22, pp. 2392-2400
Open Access | Times Cited: 255
Pathobiology and Diagnosis of Multiple Myeloma
Kevin E. Brigle, Barbara Rogers
Seminars in Oncology Nursing (2017) Vol. 33, Iss. 3, pp. 225-236
Closed Access | Times Cited: 161
LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma
Nan Yang, Jinqiu Chen, Hui Zhang, et al.
Cell Death and Disease (2017) Vol. 8, Iss. 8, pp. e2975-e2975
Open Access | Times Cited: 148
Homo-PROTACs for the Chemical Knockdown of Cereblon
Christian Steinebach, Stefanie Lindner, Namrata D. Udeshi, et al.
ACS Chemical Biology (2018) Vol. 13, Iss. 9, pp. 2771-2782
Closed Access | Times Cited: 134
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
Carlo G. Tocchetti, Christian Cadeddu Dessalvi, Daniela Di Lisi, et al.
Antioxidants and Redox Signaling (2017) Vol. 30, Iss. 18, pp. 2110-2153
Open Access | Times Cited: 114
New and emerging therapies for acute and chronic graftversushost disease
LaQuisa C. Hill, Amin M. Alousi, Partow Kebriaei, et al.
Therapeutic Advances in Hematology (2017) Vol. 9, Iss. 1, pp. 21-46
Open Access | Times Cited: 103
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
Panagiotis Efentakis, Georgios Kremastiotis, Aimilia Varela, et al.
Blood (2018) Vol. 133, Iss. 7, pp. 710-723
Open Access | Times Cited: 101
RETRACTED ARTICLE: Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression
Li Chen, Ning Hu, Chao Wang, et al.
Cell Cycle (2017) Vol. 17, Iss. 3, pp. 319-329
Open Access | Times Cited: 89
Apoptotic Extracellular Vesicles Ameliorate Multiple Myeloma by Restoring Fas-Mediated Apoptosis
Juan Wang, Zeyuan Cao, Panpan Wang, et al.
ACS Nano (2021) Vol. 15, Iss. 9, pp. 14360-14372
Open Access | Times Cited: 86
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Salihanur Darici, Hazem Alkhaldi, Gillian Horne, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2934-2934
Open Access | Times Cited: 85
MIR145-3ppromotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targetingHDAC4
Hong-Kun Wu, Chang Liu, Qingyuan Yang, et al.
Autophagy (2019) Vol. 16, Iss. 4, pp. 683-697
Open Access | Times Cited: 81
Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
Anne Slomp, Laura M Moesbergen, Jianan Gong, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4202-4214
Open Access | Times Cited: 77
Emerging agents and regimens for multiple myeloma
Yang Yang, Yi Li, Huiyao Gu, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 72
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Luciano J. Costa, Faith E. Davies, Gregory Monohan, et al.
Blood Advances (2021) Vol. 5, Iss. 19, pp. 3748-3759
Open Access | Times Cited: 63
IRF4 in multiple myeloma—Biology, disease and therapeutic target
Alessandro Agnarelli, Tim Chevassut, Erika J. Mancini
Leukemia Research (2018) Vol. 72, pp. 52-58
Open Access | Times Cited: 61
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Even H. Rustad, Eivind Coward, Emilie Ranheim Skytøen, et al.
Haematologica (2017) Vol. 102, Iss. 7, pp. 1266-1272
Open Access | Times Cited: 56
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Saurabh Chhabra
Pharmaceuticals (2017) Vol. 10, Iss. 2, pp. 40-40
Open Access | Times Cited: 49
Multiple Myeloma Associated Bone Disease
Stine Rasch, Thomas Lund, Jon Thor Asmussen, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2113-2113
Open Access | Times Cited: 45
Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1
Chunming Gu, Zhao Yin, Hong Nie, et al.
BMC Biology (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 44
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang, Pan Wu, Qian Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113473-113473
Closed Access | Times Cited: 41
KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma
Yue Wu, Y. Luo, Xingchen Yao, et al.
Cell Biology and Toxicology (2024) Vol. 40, Iss. 1
Open Access | Times Cited: 5
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Philippe Moreau, Edwin de Wit
British Journal of Haematology (2017) Vol. 179, Iss. 2, pp. 198-218
Open Access | Times Cited: 41
The role of deubiquitinating enzymes in cancer drug resistance
Parthasaradhireddy Tanguturi, Kye-Seong Kim, Suresh Ramakrishna
Cancer Chemotherapy and Pharmacology (2020) Vol. 85, Iss. 4, pp. 627-639
Closed Access | Times Cited: 38
Page 1 - Next Page

Scroll to top